

1 **Comparison of excess deaths and laboratory-confirmed COVID-19 deaths**  
2 **during a large Omicron epidemic in 2022 in Hong Kong**

3 Hualei Xin<sup>1,2</sup>, Alexandra H. T. Law<sup>2</sup>, Justin K. Cheung<sup>2</sup>, Yun Lin<sup>2</sup>, Peng Wu<sup>2,3</sup>,  
4 Zhongjie Li<sup>1</sup>, Benjamin J. Cowling<sup>2,3</sup>, Weizhong Yang<sup>1</sup>, Jessica Y. Wong<sup>2</sup>

5

6 **Affiliations:**

7 1. School of Population Medicine and Public Health, Chinese Academy of Medical  
8 Sciences & Peking Union Medical College, Beijing, China.

9 2. World Health Organization Collaborating Centre for Infectious Disease  
10 Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of  
11 Medicine, The University of Hong Kong, Hong Kong Special Administrative  
12 Region, China

13 3. Laboratory of Data Discovery for Health Limited, Hong Kong Science and  
14 Technology Park, New Territories, Hong Kong Special Administrative Region,  
15 China

16

17 **Corresponding authors:**

18 Peng Wu, School of Public Health, Li Ka Shing Faculty of Medicine, The University  
19 of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong.

20 Tel: +852 3917 6746; Fax: +852 3520 1945; email: [pengwu@hku.hk](mailto:pengwu@hku.hk)

21

22 Weizhong Yang, School of Population Medicine and Public Health, Chinese  
23 Academy of Medical Sciences & Peking Union Medical College, 7 Dongdan  
24 Santiao, Dongcheng District, Beijing, China.

25 Tel: +86 139 1181 9068; email: [yangweizhong@cams.cn](mailto:yangweizhong@cams.cn)

26

27 **Running head:** Comparison of Excess deaths and COVID-19 deaths

28 Word count (abstract): 282

29 Word count (main text): 2,629

30 **Key words:** COVID-19, Excess mortality, laboratory-confirmed COVID-19

31 mortality, Omicron, Elimination

32

33

34 **ABSTRACT**

35 **Background:** Using a local elimination strategy, Hong Kong was able to minimize  
36 COVID-19 mortality in 2020 and 2021, but a large epidemic caused by the Omicron  
37 variant occurred in 2022. We aimed to estimate the overall, age-, sex-, epidemic  
38 period- and cause-specific excess mortality in 2022 in Hong Kong and compared  
39 excess mortality to laboratory-confirmed COVID-19 mortality.

40 **Methods:** Negative binomial regression analysis was used to model time series of  
41 weekly all-cause and cause-specific deaths from 2010 to 2021 to predict the weekly  
42 number of deaths in 2022 against counterfactual baselines projected from the trends  
43 in the absence of a pandemic. The estimated excess deaths were compared with  
44 laboratory-confirmed COVID-19 deaths overall and by age and epidemic period.

45 **Results:** We estimated that there were 13,500 (95% CI: 13,400-13,600) excess  
46 deaths in 2022, which was slightly higher than the 12,228 deaths recorded with  
47 laboratory-confirmed COVID-19, with the majority of the excess deaths and  
48 laboratory-confirmed deaths occurring among older adults. The increased number of  
49 excess deaths over laboratory-confirmed COVID-19 deaths was most substantial  
50 from February to April 2022 (a difference of 847 deaths), when the largest Omicron  
51 wave peaked. Most of the excess deaths (78%) were from respiratory causes, while  
52 10% were from cardiovascular causes. A slight reduction in malignant neoplasm  
53 mortality was identified among older adults in 2022.

54 **Conclusions:** A substantial increase in population mortality was identified in 2022  
55 in Hong Kong, slightly larger than the laboratory-confirmed COVID-19 deaths.  
56 Apart from the possibility of underdiagnosis, excess deaths might also be attributed  
57 to the overload of healthcare resources during the pandemic. Deaths from  
58 COVID-19 may have displaced some deaths that would otherwise have occurred

59 due to other causes although we did not find evidence of substantial mortality

60 displacement.

61

62

## 63 INTRODUCTION

64 Since the emergence of SARS-CoV-2 at the end of 2019, millions of COVID-19  
65 deaths with infection of the virus have been recorded globally (1). However, the  
66 reported number may not represent the full mortality impact associated with the  
67 COVID-19 pandemic for several reasons. First, some COVID-19 deaths may be  
68 assigned to other causes due to misclassification or misdiagnosis, particularly during  
69 the early phase of the pandemic when the diagnostic capacity was more limited (2,  
70 3). Second, there may have been indirect health impact due to the disruption of  
71 essential medical services due to pressure on the health-system (3), changes in  
72 medical behavior resulting from difficulty in accessing healthcare services (4, 5), or  
73 fear of getting infected in medical institutions or delays in seeking healthcare under  
74 stay-at-home policies or other social distancing measures (5, 6). Excess mortality is  
75 the difference between the observed and expected mortality obtained under some  
76 counterfactual scenario (7, 8). This indicator has long been used to estimate the  
77 disease burden of past health crises or pandemics based on mortality time-series  
78 (8-10). For the COVID-19 pandemic, the World Health Organization (WHO)  
79 estimated 14.83 million excess deaths in 2020 and 2021, which is 2.74 times higher  
80 than the reported deaths (5.42 million) from laboratory-confirmed SARS-CoV-2  
81 infections (3).

82

83 Hong Kong adopted an elimination strategy during the COVID-19 pandemic in  
84 2020 and 2021 (11). Individual and population interventions were introduced, such  
85 as universal isolation of confirmed cases, strict quarantine of close contacts, school  
86 closures and other compulsory social distancing measures (12). These measures  
87 effectively controlled pre-Omicron transmission resulting in 181 (2 per 100,000)

88 local laboratory-confirmed COVID-19 deaths in 2020 and 30 (0.4 per 100,000) in  
89 2021 (12). However, our previous study estimated an estimated 1,800 excess deaths  
90 from diseases other than COVID-19 in 2020, potentially related to delays or  
91 reductions in healthcare seeking as a consequence of strict public health and social  
92 measures (5). In early 2022 Hong Kong experienced a very large Omicron epidemic  
93 in the early period of the year, with over 2 million confirmed COVID-19 cases (by  
94 RT-PCR or rapid antigen tests) and 10,000 deaths reported (136 per 100,000) (12).

95

96 The considerable excess mortality identified during the elimination phase with  
97 minimal transmission of COVID-19 (5) prompted us to investigate mortality impact  
98 of COVID-19 over a much larger epidemic caused by Omicron subvariants in Hong  
99 Kong by estimating the excess mortality in 2022 by age, sex, epidemic period, and  
100 cause of death, and comparing the excess mortality to the reported fatal cases with  
101 confirmed COVID-19.

102

## 103 **METHODS**

### 104 *Sources of data*

105 Individual death data from 2010 to 2022 were obtained from the Census and  
106 Statistics Department of Hong Kong. Weekly mortality data were aggregated into  
107 groups of age (0-4, 5-14, 15-44, 45-64, 65-79 and  $\geq 80$ ), sex, and cause of death.  
108 Cause of deaths were coded by the International Classification of Diseases Tenth  
109 Revision (ICD-10) and grouped into: all causes (A00-Z99), and the following major  
110 causes: respiratory diseases (J00-J99), malignant neoplasms (C00-C97),  
111 cardiovascular diseases (I00-I99), kidney diseases (N00-N07, N17-N19, N25-N27),  
112 external causes (S00-T88), diabetes mellitus (E10-E14), and other causes (including

113 diseases of the digestive system, mental and behavioral disorders, certain infectious  
114 and parasitic diseases, diseases of the nervous system, et al.). Data on individual  
115 patients with laboratory-confirmation of SARS-CoV-2 in 2022 were obtained from  
116 the Hong Kong Hospital Authority (HA), Centre for Health Protection and Deaths  
117 Registry (13). Epidemiological information of individual patients was provided in  
118 the database, including age, sex, date of laboratory confirmation, occurrence of  
119 death in-hospital or out-of-hospital. In this analysis, a laboratory-confirmed  
120 COVID-19 death was defined as a person who had a positive RT-qPCR result  
121 testing for SARS-CoV-2 with a respiratory specimen collected within 28 days  
122 before or seven days after the date of death. The annual mid-year population data by  
123 age and sex between 2010 and 2022 were collected from the Census and Statistics  
124 Department (14).

125

### 126 *Statistical analysis*

127 Weekly mortality risk was calculated by dividing the number of weekly deaths by  
128 mid-year populations in Hong Kong, by age, sex, and cause of death. We applied  
129 negative binomial regression models to the time series of weekly number of  
130 all-cause and disease-specific deaths from 2010 to 2021, assuming the temporal  
131 mortality in 2010-21 extending to 2022. In each regression model, we included the  
132 population size as an offset and accounted for long-term trends using the calendar  
133 year. Fourier terms with the variable “week” were included in the regression models  
134 to allow for annual seasonality. Another covariate was included in the model to  
135 account for changes in the mortality trend in Hong Kong since the emergence of  
136 SARS-CoV-2 in January 2020. The COVID-19-associated excess mortality risk was  
137 calculated by subtracting the predicted weekly mortality risk from the fitted

138 regression model from the observed weekly mortality risk. Performance of the  
139 model was examined using the Akaike Information Criterion (AIC) during the  
140 model proceeding.

141

142 In 2022, Hong Kong experienced two major epidemics driven by Omicron  
143 subvariants, including the largest wave during February - April and a smaller wave  
144 from November onwards. We defined weeks 1-26 as period 1 (wave 5), weeks  
145 27-45 as period 2 (wave 6a), and weeks 46-52 as period 3 (wave 6b) (12). The  
146 all-cause excess mortality was estimated for these three periods using the same  
147 method described above and compared with the reported COVID-19 mortality for  
148 each period. Further technical details of the statistical methods are provided in the  
149 Appendix. All statistical analyses were conducted in R, version 4.1.0 (R Foundation  
150 for Statistical Computing, Vienna, Austria).

151

152 Our study received ethical approval from the Institutional Review Board of the  
153 University of Hong Kong/Hospital Authority Hong Kong West Cluster.

154

## 155 **RESULTS**

156 An overall increasing trend of annual mortality in Hong Kong was observed from  
157 2010 through to 2022, with a slight increase from 596 per 100,000 population in  
158 2010 to 645 in 2019, and a sharp rise to 864 in 2022 (Figure 1A). Prior to 2022, the  
159 weekly mortality peaked in late December to January every year while a prominent  
160 peak was noted in February - March in 2022, in line with the trend in confirmed  
161 COVID-19 case numbers (Figure 1A, Figure 1B). In 2022, people aged 80 years or  
162 above had the highest mortality, followed by individuals aged 65-79 years, and the



163 mortality risk was generally higher in males than females. The top three causes of  
164 death in 2022 were respiratory diseases (302 per 100,000 population), malignant  
165 neoplasms (202), and cardiovascular diseases (152), which differed from 2020 and  
166 2021 when malignant neoplasms (197 and 203 in 2020 and 2021, respectively) were  
167 the leading cause, followed by respiratory (151 and 157) and cardiovascular (137  
168 and 140) diseases (Table S1).

169

170 In total, there were 63,484 deaths (864 per 100,000 population) recorded by the  
171 death registry in 2022. With the predicted counterfactual mortality baseline of  
172 49,966 deaths (680, 95% CI: 678, 682, per 100,000 population), the excess mortality  
173 in 2022 was estimated to be 184 per 100,000 (95% CI: 182, 186), equating to an  
174 estimated 13,518 (95% CI: 13,403-13,633) additional deaths and a 27% increase in  
175 all-cause mortality (Figures 1A and 2A, Table S2). People aged 80 years or above  
176 showed the highest excess mortality risk in 2022 (2,354 per 100,000 population, 95%  
177 CI: 2,330-2,378) throughout the three defined epidemic periods, followed by 65-74  
178 years (260, 95% CI: 255-265), accounting for 68% and 22% of all excess deaths in  
179 this year, respectively (Figure 2, Table S2). Overall males (232, 95% CI: 230-235  
180 per 100,000) showed a higher excess mortality than females (143, 142-145) and sex  
181 differences were indicated in most age groups, particularly people over 80 years  
182 (2,897 excess deaths, 95% CI: 2,858-2,935 for males vs 1,960, 1,930-1,991 for  
183 females). Less than 2% of the estimated excess deaths were identified in individuals  
184 younger than 45 years (Figure S1A, Table S2).

185

186 Compared with 12,228 individuals died with confirmed COVID-19 recorded in  
187 2022 (166 deaths per 100,000 population, 95% CI: 164-169), the slightly higher

188 estimate of the excess mortality (184 per 100,000 population, 95% CI: 182-186) for  
189 the same year shared similar age-, sex-, and period-specific patterns (Figure 2A).  
190 Older adults over 80 years of age contributed to most of the differences between  
191 excess deaths and the reported COVID-19 deaths (44%, 567/1290 deaths increased),  
192 followed by those aged 65-79 years (287, 22%) and 45-64 years (236, 18%) (Figure  
193 2A, Table S3). The excess mortality was also higher than the reported COVID-19  
194 mortality for both males (232 vs 212 per 100,000 population) and females (143 vs  
195 128). The sex- and age-specific analysis indicated that 63% of the overall difference  
196 between the excess and reported deaths in females was attributed to patients over 80  
197 years of age. However, the death difference in males was contributed by the four  
198 adult groups, 15-44 (20%), 45-64 (30%), 65-79 (23%), and those over 80 years  
199 (27%) similarly (Figure S2, Figure S3).

200

201 Among the 7 causes of death investigated in this study, excess mortality was  
202 identified in 2022 for these major causes except for malignant neoplasms (Figure 3,  
203 Figure S4). The highest excess mortality risk was estimated for respiratory diseases  
204 (145 per 100,000 population, 95% CI: 144-146) and cardiovascular diseases (17, 95%  
205 CI: 16-18), representing 92% and 13% increase from the estimated baseline,  
206 respectively. The additional deaths from the two causes accounted for 88% of all  
207 excess deaths estimated for 2022 (Figure 3, Table S2). The reported mortality from  
208 malignant neoplasms (202 per 100,000 population) was slightly lower than the  
209 predicted (205, 95% CI: 204-207), with the largest reduction in people over 80 years  
210 (reduced by 25 per 100,000 population, 95% CI: 18-32), followed by those 65-79  
211 years (6, 95% CI: 3-9) (Figure 3B, Table S2).

212

213 The higher number of excess deaths over reported COVID-19 deaths in 2022 was  
214 most prominent in period 1 (weeks 1-26, 847 more deaths, 95% CI: 762-932),  
215 accounting for about 66% (847/1290) of the overall difference (Figure 2B-D, Table  
216 S3). Among these, the majority occurred in older adults over 80 years of age  
217 (624/847,74%) (Figure 2B). During period 2, however, the estimated excess deaths  
218 in people over 80 years were lower than the reported COVID-19 deaths (-128, 95%  
219 CI: -179, -77) although the age group 65-79 years showed the highest increase in the  
220 number of excess deaths over the reported COVID-19 deaths (151, 120-183) among  
221 all age groups, followed by 15-44 years (116, 109-123) (Figure 2C, Table S3). In  
222 period 3, people aged over 80 (over 71, 34-107) and 45-64 (over 73, 60-86) showed  
223 a similar number of increases (Figure 2D, Table S3). The increased number of  
224 excess deaths over confirmed COVID-19 deaths was identified in all epidemic  
225 periods for both males and females (Figure S2, Figure S3).

226

## 227 **DISCUSSION**

228 We estimated that the excess mortality associated with the COVID-19 pandemic in  
229 2022 was 184 (95% CI: 182, 186) per 100,000 population, 27% higher than the  
230 baseline mortality predicted for the year based on the historical trend. The estimated  
231 excess mortality was not only identified in causes of respiratory diseases, but also  
232 other causes, such as cardiovascular diseases, accounting for 10% of the overall  
233 excess deaths in 2022, particularly among older adults at age of 80 years or above. A  
234 slightly higher number of excess deaths than the reported COVID-19 deaths was  
235 observed mainly in the older adults during the peak of the Omicron BA.2 wave in  
236 early 2022.

237

238 A close concordance was indicated in our study between the estimated number of  
239 excess deaths and the officially recorded deaths with a confirmation of COVID-19  
240 in 2022. Globally, a report from the World Health Organization found that the  
241 excess mortality in 2020 and 2021 was 2.74 times higher than the reported  
242 COVID-19 mortality (3). A series of excess mortality studies conducted in the US  
243 found that among the overall excess deaths estimated during the pandemic, only  
244 65%-72% were attributed to COVID-19 (15-18). Hong Kong had very substantial  
245 laboratory testing capacity, testing approximately 3% of the population each day  
246 during March 2022 which included routine on-admission testing in hospitals (12).  
247 Nevertheless in our previous analysis of population mortality in Hong Kong in 2020  
248 we found an increase in cardiovascular mortality with very few COVID-19 deaths,  
249 potentially attributable to changes in healthcare seeking behaviours or disruption in  
250 care for older individuals with cardiovascular diseases (5), and this has also been  
251 reported in other locations (15-19). In the present analysis we did not observe a  
252 substantial indirect impact of the pandemic on mortality from other causes, although  
253 some indirect impact likely occurred and is included as part of the overall excess  
254 mortality.

255

256 One notable difference between the substantial mortality impact of COVID-19 in  
257 Hong Kong compared with other locations is that the impact in Hong Kong occurred  
258 in 2022, whereas highest excess mortality rates in the pandemic in other parts of the  
259 world generally occurred in 2020 and early 2021 prior to the availability of  
260 COVID-19 vaccines (3, 21, 22). We have reported separately that vaccination  
261 uptake in older adults in Hong Kong was low for various reasons (12, 23, 24),  
262 leading to a substantial mortality impact in the Omicron BA.2 wave in March-April

263 2022 (25). We also reported that case fatality rates increased by 3-fold during the  
264 peak weeks of the Omicron wave compared to earlier and later in that epidemic (26),  
265 likely due to the extreme pressure on healthcare resources at that time.

266

267 The higher number of excess deaths than the deaths with confirmed COVID-19 in  
268 Hong Kong in 2022 identified mainly in older adults during the peak of the Omicron  
269 wave in this study might also be the consequence of the large number of infections  
270 and the relatively lower vaccination coverage in the elderly (12). In contrast,  
271 countries such as Canada and Norway estimated a lower excess all-cause mortality  
272 during the Omicron epidemic than the reported COVID-19 mortality (18). It could  
273 be explained that many laboratory-confirmed COVID-19 deaths particularly in very  
274 frail older adults were actually deaths “with COVID-19” rather than “due to  
275 COVID-19”, which were counted as COVID-19 deaths but not changing the overall  
276 mortality rate (2, 20). Consequently, the death rate from causes other than  
277 COVID-19 may be reduced due to mortality displacement, and this might explain  
278 the reduction we observed in deaths from malignant neoplasms in the Hong Kong  
279 population throughout 2022 as well as the relatively lower excess deaths in older  
280 adults over months after the largest omicron wave in comparison with the confirmed  
281 COVID-19 deaths.

282

283 A number of limitations exist in this study. First, we were not able to separate the  
284 direct impact from indirect impact of the COVID-19 pandemic in the estimated  
285 excess deaths. Previously Lee et al. intended to achieve the separation by including  
286 covariates representing the two types of impact in the regression model (19). Future  
287 studies are needed to clearly define the different impact and develop valid methods

288 to make a causal inference on the health impact caused by COVID-19. Second, the  
289 accuracy of the estimated excess mortality for some defined groups in the analysis,  
290 such as children aged 5-14 years, might be limited by the small numbers of weekly  
291 deaths. Third, weekly death data from 2010 to 2021 was used to obtain the predicted  
292 weekly deaths in 2022. Different from previous studies which often used the data  
293 before 2020 as the mortality baseline, our baseline was determined based on the  
294 historical mortality trend as well as allowing for possible changes during the  
295 COVID-19 pandemic. Therefore, a direct comparison of our estimates with others  
296 may not be entirely appropriate.

297

298 In conclusion, a substantial number of excess deaths were identified in Hong Kong  
299 during a large Omicron predominant COVID-19 epidemic, and the slightly higher  
300 number of excess deaths over reported laboratory-confirmed COVID-19 deaths  
301 demonstrated the importance of pandemic responses with effective pharmaceuticals  
302 in particular vaccines in reducing the overall health burden especially in older adults.  
303 We did not identify substantial mortality displacement from other causes of death in  
304 2022.

305 **ACKNOWLEDGMENTS**

306 The authors thank Julie Au for technical support.

307

308 **FUNDING**

309 This project was financially supported by the Health and Medical Research Fund  
310 from the Health Bureau of the Government of the Hong Kong Special  
311 Administrative Region (grant no: CID-HKU2-14), and by a grant from the Research  
312 Grants Council of the Hong Kong Special Administrative Region, China (Project No.  
313 T11-705/21-N).

314

315 **AUTHOR CONTRIBUTIONS**

316 All authors meet the ICMJE criteria for authorship. The study was conceived by  
317 BJC, PW and WY. HX, JYW, AHTL and JKC analyzed the data. HX wrote the first  
318 draft of the manuscript. All authors provided critical review and revision of the text  
319 and approved the final version.

320

321 **DATA SHARING STATEMENT**

322 Restrictions apply to the availability of these data. The mortality data are available  
323 for access with the permission from the Hospital Authority and the Census and  
324 Statistics Department of Hong Kong.

325

326 **POTENTIAL CONFLICTS OF INTEREST**

327 B.J.C. has consulted for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon,  
328 Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. All other authors report no  
329 potential conflicts of interest.





331 **REFERENCES**

- 332 1. World Health Organization. WHO COVID-19 dashboard.  
333 <https://data.who.int/dashboards/covid19/cases?n=c>. Accessed 3 May 2024.
- 334 2. Stokes AC, Lundberg DJ, Elo IT, Hempstead K, Bor J, Preston SH. COVID-19  
335 and excess mortality in the United States: A county-level analysis. *PLoS medicine*.  
336 2021;18(5):e1003571.
- 337 3. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S,  
338 Wakefield J. The WHO estimates of excess mortality associated with the COVID-19  
339 pandemic. *Nature*. 2023;613(7942):130-7.
- 340 4. Marijon E, Karam N, Jost D, Perrot D, Frattini B, Derkenne C, et al.  
341 Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a  
342 population-based, observational study. *The Lancet Public health*.  
343 2020;5(8):e437-e43.
- 344 5. Xin H, Wu P, Wong JY, Cheung JK, Lau EHY, Leung GM, et al.  
345 Hospitalizations and mortality during the first year of the COVID-19 pandemic in  
346 Hong Kong, China: An observational study. *The Lancet regional health Western*  
347 *Pacific*. 2023;30:100645.
- 348 6. Kiss P, Carcel C, Hockham C, Peters SAE. The impact of the COVID-19  
349 pandemic on the care and management of patients with acute cardiovascular disease:  
350 a systematic review. *European heart journal Quality of care & clinical outcomes*.  
351 2021;7(1):18-27.
- 352 7. Woodruff BA. Interpreting mortality data in humanitarian emergencies. *Lancet*  
353 (London, England). 2006;367(9504):9-10.
- 354 8. Leon DA, Shkolnikov VM, Smeeth L, Magnus P, Pechholdová M, Jarvis CI.  
355 COVID-19: a need for real-time monitoring of weekly excess deaths. *Lancet*

- 356 (London, England). 2020;395(10234):e81.
- 357 9. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential  
358 global pandemic influenza mortality on the basis of vital registry data from the  
359 1918-20 pandemic: a quantitative analysis. *Lancet* (London, England).  
360 2006;368(9554):2211-8.
- 361 10. Beaney T, Clarke JM, Jain V, Golestaneh AK, Lyons G, Salman D, et al. Excess  
362 mortality: the gold standard in measuring the impact of COVID-19 worldwide?  
363 *Journal of the Royal Society of Medicine*. 2020;113(9):329-34.
- 364 11. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response  
365 strategy for covid-19 and other emerging pandemic diseases. *BMJ* (Clinical research  
366 ed). 2020;371:m4907.
- 367 12. Yang B, Lin Y, Xiong W, Liu C, Gao H, Ho F, et al. Comparison of control and  
368 transmission of COVID-19 across epidemic waves in Hong Kong: an observational  
369 study. *The Lancet regional health Western Pacific*. 2024;43:100969.
- 370 13. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al.  
371 Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac  
372 against COVID-19 in Hong Kong: a population-based observational study. *The*  
373 *Lancet Infectious diseases*. 2022;22(10):1435-43.
- 374 14. Census and Statistics Department. Population Estimates.  
375 <https://www.censtatd.gov.hk/en/scode150.html>. Accessed 3 May 2024.
- 376 15. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess Deaths  
377 From COVID-19 and Other Causes, March-April 2020. *Jama*. 2020;324(5):510-3.
- 378 16. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L, Taylor DDH.  
379 Excess Deaths From COVID-19 and Other Causes, March-July 2020. *Jama*.  
380 2020;324(15):1562-4.

- 381 17. Woolf SH, Chapman DA, Sabo RT, Zimmerman EB. Excess Deaths From  
382 COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021. *Jama*.  
383 2021;325(17):1786-9.
- 384 18. Bilinski A, Thompson K, Emanuel E. COVID-19 and Excess All-Cause  
385 Mortality in the US and 20 Comparison Countries, June 2021-March 2022. *Jama*.  
386 2023;329(1):92-4.
- 387 19. Lee WE, Woo Park S, Weinberger DM, Olson D, Simonsen L, Grenfell BT, et al.  
388 Direct and indirect mortality impacts of the COVID-19 pandemic in the United  
389 States, March 1, 2020 to January 1, 2022. *eLife*. 2023;12.
- 390 20. Acosta E. Global estimates of excess deaths from COVID-19. *Nature*.  
391 2023;613(7942):31-3.
- 392 21. Estimating excess mortality due to the COVID-19 pandemic: a systematic  
393 analysis of COVID-19-related mortality, 2020-21. *Lancet (London, England)*.  
394 2022;399(10334):1513-36.
- 395 22. Pallari CT, Achilleos S, Quattrocchi A, Gabel J, Critselis E, Athanasiadou M, et  
396 al. Magnitude and determinants of excess total, age-specific and sex-specific  
397 all-cause mortality in 24 countries worldwide during 2020 and 2021: results on the  
398 impact of the COVID-19 pandemic from the C-MOR project. *BMJ global health*.  
399 2024;9(4).
- 400 23. Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in  
401 factors associated with COVID-19 vaccine hesitancy and uptake among adults in  
402 Hong Kong: Serial cross-sectional surveys. *The Lancet regional health Western*  
403 *Pacific*. 2022;23:100441.
- 404 24. Yuan J, Lam WWT, Xiao J, Ni MY, Cowling BJ, Liao Q. Why Do Chinese  
405 Older Adults in Hong Kong Delay or Refuse COVID-19 Vaccination? A Qualitative

406 Study Based on Grounded Theory. The journals of gerontology Series B,  
407 Psychological sciences and social sciences. 2023;78(4):736-48.  
408 25. Mefsin YM, Chen D, Bond HS, Lin Y, Cheung JK, Wong JY, et al.  
409 Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong,  
410 January-March 2022. Emerging infectious diseases. 2022;28(9):1856-8.  
411 26. Wong JY, Cheung JK, Lin Y, Bond HS, Lau EHY, Ip DKM, et al. Intrinsic and  
412 Effective Severity of Coronavirus Disease 2019 Cases Infected With the Ancestral  
413 Strain and Omicron BA.2 Variant in Hong Kong. The Journal of infectious diseases.  
414 2023;228(9):1231-9.  
415

416 **FIGURE LEGENDS**

417 **Figure 1. The overall trend of mortality and excess deaths in 2022 in Hong**

418 **Kong. A)** Weekly observed (black dots) and predicted (red solid line and the pink

419 shaded area show the mean predicted weekly mortality and 95% confidence

420 intervals, respectively) mortality from 2010 to 2022 in Hong Kong. **B)** Predicted

421 weekly numbers of excess deaths (red solid line and the pink shaded area show the

422 mean weekly numbers of excess deaths and 95% CI, respectively), weekly numbers

423 of reported COVID-19 deaths (purple bars) and weekly numbers of locally infected

424 COVID-19 cases in Hong Kong in 2022.

425

426 **Figure 2. Overall and age-specific excess mortality and reported COVID-19**

427 **mortality in 2022. A)** Comparison of excess mortality and reported COVID-19

428 mortality overall and by age in 2022. **B)** Comparison of excess mortality and

429 reported COVID-19 mortality overall and by age in weeks 1-26 in 2022. **C)**

430 Comparison of excess mortality and reported COVID-19 mortality overall and by

431 age in weeks 27-45 in 2022. **D)** Comparison of excess mortality and reported

432 COVID-19 mortality overall and by age in weeks 46-52 in 2022.

433

434 **Figure 3. Cause-specific excess mortality by age and sex in Hong Kong in 2022.**

435 **A)** Excess mortality by age and sex for respiratory diseases. **B)** Malignant


436 neoplasms. **C)** Cardiovascular diseases. **D)** Kidney diseases. **E)** External causes. **F)**

437 Diabetes mellitus. **G)** Others (deaths from all other causes except those causes


438 shown in panels A-F).

439


### A: Weekly observed and predicted mortality from 2010 to 2022




### B: Weekly excess deaths, reported COVID-19 deaths and cases in 2022




**A: Excess mortality and reported COVID-19 mortality overall and by age in 2022**



**B: Excess mortality and reported COVID-19 mortality overall and by age in weeks 1-26 in 2022**



**C: Excess mortality and reported COVID-19 mortality overall and by age in weeks 27-45 in 2022**



**D: Excess mortality and reported COVID-19 mortality overall and by age in weeks 46-52 in 2022**

